Payment overview · 2025
General Payments
$16.27
1 reported records · 1 companies
Healthcare provider profile · identity verified
Sanjay Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WALTERBORO, SC · NPI 1275632309
Verified facts
What the public records show
CMS Open Payments records show Sanjay Kumar, MD received $16.27 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.27 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1146 | 367 |
| Losartan Potassium | Losartan Potassium | 769 | 239 |
| Hydralazine Hcl | Hydralazine Hcl | 649 | 184 |
| Jardiance | Empagliflozin | 573 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 565 | 171 |
| Gabapentin | Gabapentin | 323 | 98 |
| Furosemide | Furosemide | 308 | 97 |
| Lisinopril | Lisinopril | 297 | 86 |
| Carvedilol | Carvedilol | 289 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 286 | 78 |
| Doxazosin Mesylate | Doxazosin Mesylate | 281 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 85 |
| Spironolactone | Spironolactone | 271 | 78 |
| Metformin Hcl | Metformin Hcl | 266 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 260 | 77 |
| Omeprazole | Omeprazole | 255 | 72 |
| Allopurinol | Allopurinol | 249 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 62 |
| Calcitriol | Calcitriol | 208 | 65 |
| Farxiga | Dapagliflozin Propanediol | 200 | 47 |
| Eliquis | Apixaban | 190 | 50 |
| Sevelamer Carbonate | Sevelamer Carbonate | 182 | 60 |
| Sertraline Hcl | Sertraline Hcl | 179 | 37 |
| Ozempic | Semaglutide | 166 | 41 |
| Tradjenta | Linagliptin | 156 | 29 |
| Clonidine Hcl | Clonidine Hcl | 151 | 47 |
| Glimepiride | Glimepiride | 151 | 40 |
| Chlorthalidone | Chlorthalidone | 150 | 45 |
| Famotidine | Famotidine | 135 | 54 |
| Potassium Chloride | Potassium Chloride | 126 | 37 |
| Montelukast Sodium | Montelukast Sodium | 124 | 35 |
| Indapamide | Indapamide | 123 | 52 |
| Mirtazapine | Mirtazapine | 122 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 31 |
| Buspirone Hcl | Buspirone Hcl | 104 | 23 |
| Bumetanide | Bumetanide | 100 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 29 |
| Nifedipine Er | Nifedipine | 87 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 19 |
| Trazodone Hcl | Trazodone Hcl | 86 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 27 |
| Lokelma | Sodium Zirconium Cyclosilicate | 85 | 25 |
| Valsartan | Valsartan | 82 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 82 | 28 |
| Calcium Acetate | Calcium Acetate | 81 | 31 |
| Simvastatin | Simvastatin | 81 | 23 |
| Atenolol | Atenolol | 74 | 18 |
| Azithromycin | Azithromycin | 69 | 52 |
| Telmisartan | Telmisartan | 69 | 23 |
| Tramadol Hcl | Tramadol Hcl | 69 | 27 |
| Entresto | Sacubitril/Valsartan | 67 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 20 |
| Meloxicam | Meloxicam | 59 | 23 |
| Trulicity | Dulaglutide | 59 | 11 |
| Colchicine | Colchicine | 58 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 23 |
| Levetiracetam | Levetiracetam | 55 | 17 |
| Mounjaro | Tirzepatide | 55 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 19 |
| Ezetimibe | Ezetimibe | 54 | 19 |
| Labetalol Hcl | Labetalol Hcl | 54 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 12 |
| Prednisone | Prednisone | 52 | 17 |
| Glyburide | Glyburide | 51 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Glipizide | Glipizide | 48 | 11 |
| Veltassa | Patiromer Calcium Sorbitex | 48 | 14 |
| Midodrine Hcl | Midodrine Hcl | 45 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | 13 |
| Clonazepam | Clonazepam | 40 | 12 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Benazepril Hcl | Benazepril Hcl | 34 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | 12 |
| Ondansetron Odt | Ondansetron | 32 | 12 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 28 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Minoxidil | Minoxidil | 30 | 12 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Clinisol | Parenteral Amino Acid 15% No.5 | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Prosol | Parenteral Amino Acid 20% No.1 | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Eplerenone | Eplerenone | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Acetazolamide | Acetazolamide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | 11 |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.27 · 1 records | Novo Nordisk Inc | Ozempic | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error